A detailed history of Morgan Stanley transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 149,228 shares of LRMR stock, worth $929,690. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,228
Previous 53,613 178.34%
Holding current value
$929,690
Previous $388,000 151.8%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.3 - $10.68 $602,374 - $1.02 Million
95,615 Added 178.34%
149,228 $977,000
Q2 2024

Oct 17, 2024

BUY
$6.33 - $9.89 $40,030 - $62,544
6,324 Added 13.37%
53,613 $388,000
Q2 2024

Aug 14, 2024

BUY
$6.33 - $9.89 $40,030 - $62,544
6,324 Added 13.37%
53,613 $388,000
Q1 2024

Oct 17, 2024

SELL
$4.2 - $13.28 $26,560 - $83,982
-6,324 Reduced 11.8%
47,289 $358,000
Q1 2024

Aug 16, 2024

SELL
$4.2 - $13.28 $37,485 - $118,524
-8,925 Reduced 15.88%
47,289 $358,000
Q1 2024

May 15, 2024

SELL
$4.2 - $13.28 $37,485 - $118,524
-8,925 Reduced 15.88%
47,289 $358,000
Q4 2023

Aug 16, 2024

BUY
$2.35 - $4.71 $6,112 - $12,250
2,601 Added 4.85%
56,214 $255,000
Q4 2023

Feb 13, 2024

BUY
$2.35 - $4.71 $74,918 - $150,154
31,880 Added 131.01%
56,214 $255,000
Q3 2023

Nov 15, 2023

SELL
$3.08 - $4.49 $24,800 - $36,153
-8,052 Reduced 24.86%
24,334 $96,000
Q2 2023

Aug 14, 2023

SELL
$3.13 - $5.27 $100,166 - $168,650
-32,002 Reduced 49.7%
32,386 $101,000
Q1 2023

May 15, 2023

SELL
$4.0 - $6.68 $1.91 Million - $3.18 Million
-476,449 Reduced 88.09%
64,388 $291,000
Q4 2022

Feb 14, 2023

BUY
$2.73 - $5.08 $28,785 - $53,563
10,544 Added 1.99%
540,837 $2.23 Million
Q3 2022

Nov 14, 2022

BUY
$1.53 - $3.64 $742 - $1,765
485 Added 0.09%
530,293 $1.7 Million
Q2 2022

Oct 27, 2022

SELL
$1.9 - $3.98 $334 - $700
-176 Reduced 0.03%
529,808 $1.04 Million
Q2 2022

Aug 15, 2022

SELL
$1.9 - $3.98 $334 - $700
-176 Reduced 0.03%
529,808 $1.04 Million
Q1 2022

Oct 27, 2022

BUY
$3.65 - $10.84 $642 - $1,907
176 Added 0.03%
529,984 $2.15 Million
Q1 2022

May 13, 2022

BUY
$3.65 - $10.84 $1.89 Million - $5.62 Million
518,189 Added 4393.29%
529,984 $2.15 Million
Q4 2021

Feb 14, 2022

SELL
$8.86 - $13.47 $206,127 - $313,379
-23,265 Reduced 66.36%
11,795 $127,000
Q3 2021

Nov 15, 2021

BUY
$9.61 - $15.11 $336,926 - $529,756
35,060 New
35,060 $404,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $270M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.